Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Cracow – page 34

1 210 clinical trials in Cracow, Poland across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Cracow at a glance
1 210
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

1 210 trials in Cracow

Open in trial search

B-cell lymphoma+1

Recruiting

Long-term Study of Ibrutinib for Patients with B-cell Non-Hodgkin's Lymphoma and Chronic Graft Versus Host Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

IgA nephropathy

Recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Nephrogenic anaemia

Recruiting

Study on Roxadustat for Treating Anemia in Children with Chronic Kidney Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Epoetin Alfa
  • Sponsor:Astellas Pharma Global Development Inc.

Neovascular age-related macular degeneration

Recruiting

Study on Vitrectomy, Alteplase, and Aflibercept for Patients with Wet Age-Related Macular Degeneration and Submacular Hemorrhage

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:King's College Hospital NHS Foundation Trust

Hereditary angioedema with C1 esterase inhibitor deficiency

Recruiting

Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Study on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer

Recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177Lu) Vipivotide Tetraxetan
  • Sponsor:Novartis Pharma AG

Breast cancer metastatic

Recruiting

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Chronic lymphocytic leukaemia+1

Recruiting

Study on Ibrutinib and Venetoclax for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Systemic lupus erythematosus

Recruiting

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Systemic lupus erythematosus

Recruiting

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Chronic cutaneous lupus erythematosus+2

Recruiting

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Cracow

What the registry says about research in the country

01 Respiratory Disease Research

Innovative studies focusing on respiratory infections and preventive measures. Current trials evaluate vaccines against RSV and human metapneumovirus in older adults, alongside investigations into chronic respiratory conditions.

  • RSV and HMPV vaccine development
  • Chronic Rhinosinusitis treatments
  • COPD management strategies

Multiple trials are exploring novel therapeutic approaches for respiratory conditions affecting various age groups.

02 Immunology and Vaccines

Comprehensive research into preventive vaccines for various conditions, including chickenpox and meningococcal infections. Studies focus on both pediatric and adult populations.

  • Varicella vaccine development
  • Meningococcal prevention
  • Influenza protection strategies

Research emphasizes vaccine safety, immune response, and efficacy across different age groups.

03 Chronic Disease Management

Advanced studies targeting chronic conditions including psoriatic arthritis and systemic diseases. Research focuses on innovative treatments and long-term management strategies.

  • Psoriasis treatments
  • Heart failure prevention
  • Obesity management

Trials evaluate new therapeutic approaches for improving patient outcomes in chronic conditions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.